Drug intelligence / Profile preview

Diquabell Plus

Development stage: Unknown
Lead developer: Chong Kun Dang Pharmaceutical
Modality: Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Ophthalmic

Overview

CKD-352 (Diquabell Plus) is a fixed-dose combination ophthalmic solution developed by Chong Kun Dang Pharmaceutical for the treatment of dry eye disease. It consists of diquafosol sodium (3%), a P2Y2 receptor agonist, and sodium hyaluronate (0.1%), a viscoelastic lubricant. Diquafosol stimulates the secretion of water and mucins from the conjunctival epithelium and goblet cells, thereby improving tear film stability. Sodium hyaluronate provides ocular surface lubrication and promotes corneal epithelial repair through its interaction with the CD44 receptor. The combination was approved by the South Korean Ministry of Food and Drug Safety (MFDS) in May 2023, following a Phase 3 clinical trial (NCT04548427) that demonstrated its efficacy and safety compared to diquafosol monotherapy.

Brand names: Diquabell Plus
Other names: Diquafosol sodium + Sodium hyaluronateDiquafosol/Sodium hyaluronate combination

Targets

CD44 (CD44 antigen)

Beyond the preview

Go deeper on Diquabell Plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diquabell Plus.

Explore the full profile